Illumina PT Raised to $202.00 (ILMN)
Equities researchers at UBS AG raised their target price on shares of Illumina (NASDAQ:ILMN) from $152.00 to $202.00 in a research report issued on Wednesday, AmericanBankingNews.com reports. The firm currently has a “buy” rating on the stock. UBS AG’s price objective would suggest a potential upside of 18.54% from the company’s current price.
Illumina (NASDAQ:ILMN) traded down 0.14% during mid-day trading on Wednesday, hitting $170.16. 1,701,551 shares of the company’s stock traded hands. Illumina has a 52-week low of $48.00 and a 52-week high of $173.98. The stock has a 50-day moving average of $139.9 and a 200-day moving average of $101.0. The company has a market cap of $21.561 billion and a P/E ratio of 189.33.
Illumina (NASDAQ:ILMN) last announced its earnings results on Tuesday, January 28th. The company reported $0.45 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.44 by $0.01. The company had revenue of $387.00 million for the quarter, compared to the consensus estimate of $382.06 million. During the same quarter in the prior year, the company posted $0.42 earnings per share. The company’s quarterly revenue was up 25.1% on a year-over-year basis. On average, analysts predict that Illumina will post $2.06 earnings per share for the current fiscal year.
A number of other firms have also recently commented on ILMN. Analysts at Bank of America raised their price target on shares of Illumina from $165.00 to $190.00 in a research note on Tuesday. Separately, analysts at Leerink Swann set a $160.00 price target on shares of Illumina in a research note on Wednesday, January 29th. Finally, analysts at Mizuho raised their price target on shares of Illumina from $150.00 to $175.00 in a research note on Wednesday, January 29th. They now have a “buy” rating on the stock. Six equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $123.41.
In other Illumina news, CEO Jay Flatley sold 30,000 shares of the stock on the open market in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $160.43, for a total value of $4,812,900.00. Following the completion of the transaction, the chief executive officer now directly owns 385,105 shares of the company’s stock, valued at approximately $61,782,395. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
Illumina, Inc (NASDAQ:ILMN) is a developer and manufacturer of life science tools and integrated systems for the analysis of genetic variation and function.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.